2Albate N. Obesity and cardiovascular disease pathogenetic role of the metabolic syndrome and therapeutic implication [ J ]. J Diabetes Complications, 2000,14 ( 4 ) : 154 -174.
3Colhoun HM, Lee ET, Bennett PH, et al. Risk factors for renal failure;the WHO multinational study of vascular disease in diabetes [ J ]. Diabetologia ,2001,44 ( 2 ) :46-53.
4Widen EIM, Eriksson JG, Greop LC. Mefformin normalizes nonoxidative glucose metabolism in insulin-resistance normoglycemic first-degree relatives of patients with NIDDM [ J ]. Diabetes, 1992,41 ( 7 ) : 354-358.
4Catalano C,Muscelli E,Quinones GA,et al.Effects of insulin on systemic and renal handing of albumin in nondiabetic and NIDDM subjects.Diabetes,1997,46(5):868～875.
5Liu ZH,Liu H,Peng A,et al.Amylin:a new component in the development of renal lesions in patients with type 2diabetes mellitus,J AM Soc Nephrol,2001,12(12):150.
6American Diabetes Association.Clinical practice recommendations 2003.Diabetes Care,2003,26:94～98.
4Alberiti K G,Zimmet P Z.Definition,diagnosis and classification of diabetes mellitus and its complications.Part 1:diagnosis and classification of diabetes mellitus provisionalreport of a WHO consultation[J].Diabetes Med,1998,15(7):539-553.
5Mogensen C E,Schmitz A,Christensen C K.Comparative renal pathophysiology relevant to IDDM and NIDDM patients[J].Diabetes Metab Rev,1988,4(5):453-483.
